Researchers at University of Zurich Release New Study Findings on Drugs and Therapies (Male depression risk, psychological distress, and psychotherapy uptake: Validation of the German version of the male depression risk scale)

摘要

2021 MAY 07 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - A new study on drugs and therapies is now available. According to news reporting out of Zurich, Switzerland, by NewsRx editors, research stated, "Screening for depressive disorders in men may be complicated by traditional male role norms. The Male Depression Risk Scale (MDRS) was developed to aid screening for depression in men adhering to traditional male role norms and to facilitate identification of depression in men in general and to promote treatment uptake." Our news journalists obtained a quote from the research from University of Zurich: "Validation of a German version of the MDRS and examination of its potential to predict clinical characteristics. In an anonymous online survey comprising of 1605 participants (male: N = 671; 42%), information was obtained on psychological distress, diagnosed psychological disorders, psychotherapy and psychopharma-cological treatment. Additional measures included a German version of the MDRS as further mental-health-related constructs. The German version of the MDRS showed good validity and reliability. The previously identified 6-factor structure could be replicated for the German version. Compared to the Patient Health Questionnaire 9, the MDRS showed similar detection performance in identifying men who self-reported psychological distress, psychological disorders, depression, psychotherapy usage, or usage of psychopharmacological therapy."